Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery : A pilot study
© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd..
SETTING: Bariatric surgery is indicated for patients diagnosed with obesity and type 2 diabetes. Many patients achieve type 2 diabetes remission soon after bariatric surgery. Even though most maintain good glycemic control, remission is not maintained in all patients, and as a result, some patients may relapse. Type 2 diabetes relapse is common in patients who regain weight; weight regain is prevalent 1 to 2 years after surgery. Additional pharmacotherapy may be required to aid bariatric surgery in fostering weight loss and reducing blood glucose levels.
OBJECTIVES: The purpose of this clinical trial was to determine the effects of canagliflozin in participants who initially achieved type 2 diabetes remission but subsequently relapsed.
METHODS: The double-blinded, randomized, and prospective study recruited participants (n = 16) roughly 3 years after bariatric surgery. The participants were followed for 6 months.
RESULTS: Body mass index (-1.24 kg/m2) and body weight (-3.7 kg) were significantly reduced with canagliflozin therapy versus placebo. There were improvements in body fat composition as denoted by reductions in android (-3.00%) and truncal (-2.67%) fat. Also, there were differences in blood glucose and hemoglobin A1C at 6 months.
CONCLUSION: After bariatric surgery, canagliflozin improved weight loss and glycemic outcomes in participants with type 2 diabetes. Canagliflozin also facilitated improvements in body fat composition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Obesity science & practice - 6(2020), 3 vom: 26. Juni, Seite 255-263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kashyap, Sangeeta R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bariatric surgery |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/osp4.409 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311029876 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311029876 | ||
| 003 | DE-627 | ||
| 005 | 20240328235440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/osp4.409 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM311029876 | ||
| 035 | |a (NLM)32523714 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kashyap, Sangeeta R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery |b A pilot study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd. | ||
| 520 | |a SETTING: Bariatric surgery is indicated for patients diagnosed with obesity and type 2 diabetes. Many patients achieve type 2 diabetes remission soon after bariatric surgery. Even though most maintain good glycemic control, remission is not maintained in all patients, and as a result, some patients may relapse. Type 2 diabetes relapse is common in patients who regain weight; weight regain is prevalent 1 to 2 years after surgery. Additional pharmacotherapy may be required to aid bariatric surgery in fostering weight loss and reducing blood glucose levels | ||
| 520 | |a OBJECTIVES: The purpose of this clinical trial was to determine the effects of canagliflozin in participants who initially achieved type 2 diabetes remission but subsequently relapsed | ||
| 520 | |a METHODS: The double-blinded, randomized, and prospective study recruited participants (n = 16) roughly 3 years after bariatric surgery. The participants were followed for 6 months | ||
| 520 | |a RESULTS: Body mass index (-1.24 kg/m2) and body weight (-3.7 kg) were significantly reduced with canagliflozin therapy versus placebo. There were improvements in body fat composition as denoted by reductions in android (-3.00%) and truncal (-2.67%) fat. Also, there were differences in blood glucose and hemoglobin A1C at 6 months | ||
| 520 | |a CONCLUSION: After bariatric surgery, canagliflozin improved weight loss and glycemic outcomes in participants with type 2 diabetes. Canagliflozin also facilitated improvements in body fat composition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bariatric surgery | |
| 650 | 4 | |a body composition | |
| 650 | 4 | |a canagliflozin | |
| 650 | 4 | |a type 2 diabetes | |
| 700 | 1 | |a Kheniser, Karim |e verfasserin |4 aut | |
| 700 | 1 | |a Aminian, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Schauer, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Le Roux, Carel |e verfasserin |4 aut | |
| 700 | 1 | |a Burguera, Bartolome |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obesity science & practice |d 2015 |g 6(2020), 3 vom: 26. Juni, Seite 255-263 |w (DE-627)NLM259741787 |x 2055-2238 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:3 |g day:26 |g month:06 |g pages:255-263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/osp4.409 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2020 |e 3 |b 26 |c 06 |h 255-263 | ||